Urban Scheuring

3.3k total citations
40 papers, 1.9k citations indexed

About

Urban Scheuring is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Urban Scheuring has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 12 papers in Hematology. Recurrent topics in Urban Scheuring's work include Chronic Myeloid Leukemia Treatments (11 papers), Acute Lymphoblastic Leukemia research (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Urban Scheuring is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Acute Lymphoblastic Leukemia research (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Urban Scheuring collaborates with scholars based in Germany, United States and Switzerland. Urban Scheuring's co-authors include Dieter Hoelzer, Cezary Szczylik, Michael Staehler, Ronald M. Bukowski, Frédéric Rolland, Bernard Escudier, Thomas E. Hutson, Sylvie Négrier, Tomasz Demkow and Oliver G. Ottmann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Urban Scheuring

38 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Urban Scheuring Germany 19 740 694 675 579 508 40 1.9k
Nathalie Contentin France 20 2.0k 2.6× 443 0.6× 259 0.4× 831 1.4× 610 1.2× 49 2.8k
H. Bodenstein Germany 17 702 0.9× 353 0.5× 667 1.0× 699 1.2× 378 0.7× 39 1.8k
Carlos Vallejo United States 25 538 0.7× 263 0.4× 346 0.5× 956 1.7× 224 0.4× 118 2.0k
John Ellerton United States 18 1.4k 1.8× 313 0.5× 395 0.6× 1.4k 2.4× 1.2k 2.3× 29 3.3k
Aruna Raghavachar Germany 22 1.5k 2.0× 164 0.2× 285 0.4× 497 0.9× 357 0.7× 55 2.1k
BH Childs United States 11 883 1.2× 127 0.2× 414 0.6× 500 0.9× 272 0.5× 20 1.9k
Hans Grünwald United States 21 789 1.1× 408 0.6× 131 0.2× 403 0.7× 365 0.7× 52 1.4k
Paolo Latini Italy 24 982 1.3× 201 0.3× 412 0.6× 885 1.5× 244 0.5× 57 2.9k
Sanam Loghavi United States 31 1.5k 2.1× 395 0.6× 119 0.2× 721 1.2× 826 1.6× 226 2.9k
Alfonso Piciocchi Italy 25 1.0k 1.4× 682 1.0× 94 0.1× 488 0.8× 330 0.6× 105 1.8k

Countries citing papers authored by Urban Scheuring

Since Specialization
Citations

This map shows the geographic impact of Urban Scheuring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urban Scheuring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urban Scheuring more than expected).

Fields of papers citing papers by Urban Scheuring

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urban Scheuring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urban Scheuring. The network helps show where Urban Scheuring may publish in the future.

Co-authorship network of co-authors of Urban Scheuring

This figure shows the co-authorship network connecting the top 25 collaborators of Urban Scheuring. A scholar is included among the top collaborators of Urban Scheuring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urban Scheuring. Urban Scheuring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garon, Edward B., Byoung Chul Cho, Niels Reinmuth, et al.. (2021). Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer. 22(4). 301–312.e8. 20 indexed citations
2.
Si, Han, Michael Kuziora, Katie Quinn, et al.. (2020). A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research. 27(6). 1631–1640. 86 indexed citations
3.
Rizvi, Naiyer A., Byoung Chul Cho, Niels Reinmuth, et al.. (2019). OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Journal of Thoracic Oncology. 14(10). S217–S217. 43 indexed citations
4.
5.
6.
Capalbo, Gianni, Steffen Koschmieder, Hans‐Ulrich Klein, et al.. (2013). Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML. Oncology Reports. 30(5). 2254–2262. 11 indexed citations
7.
Capalbo, Gianni, Stefan Klein, Ursula Dietrich, et al.. (2011). Knockdown of ERM Family Member Moesin in Host Cells Increases HIV Type 1 Replication. AIDS Research and Human Retroviruses. 27(12). 1317–1322. 8 indexed citations
8.
Capalbo, Gianni, et al.. (2011). HIV-1 Infection Suppresses Expression of Host Cell Cycle-Associated GenePDS5A. Intervirology. 55(4). 79–91. 3 indexed citations
9.
Capalbo, Gianni, et al.. (2010). Inhibition of X4-Tropic HIV Type 1 Replication by Knockdown of the Cellular Protein LEREPO4. AIDS Research and Human Retroviruses. 26(10). 1155–1161. 4 indexed citations
10.
Escudier, Bernard, Cezary Szczylik, Thomas E. Hutson, et al.. (2009). Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(8). 1280–1289. 378 indexed citations
11.
Waßmann, Barbara, Urban Scheuring, Christian Thiede, et al.. (2003). Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplantation. 31(7). 611–614. 6 indexed citations
12.
Scheuring, Urban, Roman Pfeifer, Barbara Waßmann, et al.. (2003). Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia. 17(9). 1700–1706. 29 indexed citations
13.
14.
Scheuring, Urban, H. M. Seitz, Axel Wellmann, et al.. (2003). Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination. Medical Microbiology and Immunology. 192(4). 193–195. 16 indexed citations
15.
Waßmann, Barbara, Urban Scheuring, Roman Pfeifer, et al.. (2003). Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 17(10). 1919–1924. 27 indexed citations
16.
Scheuring, Urban, Helen Sabzevari, & Argyrios N. Theofilopoulos. (2002). Proliferative arrest and cell cycle regulation in CD8+CD28− versus CD8+CD28+ T cells. Human Immunology. 63(11). 1000–1009. 46 indexed citations
17.
Gökbuget, Nicola, Michael Kneba, Thorsten Raff, et al.. (2002). Risk-adapted treatment according to minimal residual disease in adult ALL. Best Practice & Research Clinical Haematology. 15(4). 639–652. 14 indexed citations
18.
Waßmann, Barbara, Urban Scheuring, Roman Pfeifer, et al.. (2001). Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplantation. 28(7). 721–724. 19 indexed citations
19.
Scheuring, Urban, Jacques Corbeil, Donald E. Mosier, & Argyrios N. Theofilopoulos. (1998). Early modifications of host cell gene expression induced by HIV-1. AIDS. 12(6). 563–570. 29 indexed citations
20.
Uhlenbruck, G., et al.. (1988). CA 19-9, CA 50 and elastase 1 as additional markers of cystic fibrosis. Klinische Pädiatrie. 200(2). 89–95. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie Contentin Breakdown of academic impact, for papers by H. Bodenstein Breakdown of academic impact, for papers by Carlos Vallejo Breakdown of academic impact, for papers by John Ellerton Breakdown of academic impact, for papers by Aruna Raghavachar Breakdown of academic impact, for papers by BH Childs Breakdown of academic impact, for papers by Hans Grünwald Breakdown of academic impact, for papers by Paolo Latini Breakdown of academic impact, for papers by Sanam Loghavi Breakdown of academic impact, for papers by Alfonso Piciocchi
Rankless by CCL
2026